AR051889A1 - Sulfonas de tripeptido y tetrapeptido - Google Patents
Sulfonas de tripeptido y tetrapeptidoInfo
- Publication number
- AR051889A1 AR051889A1 ARP060100041A ARP060100041A AR051889A1 AR 051889 A1 AR051889 A1 AR 051889A1 AR P060100041 A ARP060100041 A AR P060100041A AR P060100041 A ARP060100041 A AR P060100041A AR 051889 A1 AR051889 A1 AR 051889A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- bone marrow
- tripeptide
- 3alkyl
- Prior art date
Links
- 210000001185 bone marrow Anatomy 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 150000005690 diesters Chemical class 0.000 abstract 2
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- -1 L-gamma-glutamyl glycol Chemical group 0.000 abstract 1
- 125000001992 L-gamma-glutamyl group Chemical group N[C@@H](CCC(=O)*)C(=O)O 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 230000003028 elevating effect Effects 0.000 abstract 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 1
- 230000011132 hemopoiesis Effects 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 230000003039 myelosuppressive effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 150000003457 sulfones Chemical class 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64193205P | 2005-01-06 | 2005-01-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR051889A1 true AR051889A1 (es) | 2007-02-14 |
Family
ID=36123437
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100041A AR051889A1 (es) | 2005-01-06 | 2006-01-05 | Sulfonas de tripeptido y tetrapeptido |
| ARP060100042A AR051890A1 (es) | 2005-01-06 | 2006-01-05 | Tioeteres de tripeptido y tetrapeptido |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100042A AR051890A1 (es) | 2005-01-06 | 2006-01-05 | Tioeteres de tripeptido y tetrapeptido |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7129215B2 (https=) |
| EP (2) | EP1833978B1 (https=) |
| JP (2) | JP4903716B2 (https=) |
| KR (2) | KR101244609B1 (https=) |
| CN (2) | CN101090977B (https=) |
| AR (2) | AR051889A1 (https=) |
| AT (2) | ATE410520T1 (https=) |
| AU (2) | AU2006204022B2 (https=) |
| BR (2) | BRPI0606520A2 (https=) |
| CA (2) | CA2587284C (https=) |
| DE (2) | DE602006003064D1 (https=) |
| DK (2) | DK1833978T3 (https=) |
| EA (2) | EA200701398A1 (https=) |
| ES (2) | ES2314890T3 (https=) |
| HR (2) | HRP20090128T3 (https=) |
| IL (2) | IL182836A (https=) |
| MX (2) | MX2007008255A (https=) |
| NZ (2) | NZ555362A (https=) |
| PL (2) | PL1833978T3 (https=) |
| PT (2) | PT1833978E (https=) |
| SI (2) | SI1833978T1 (https=) |
| TW (2) | TWI317739B (https=) |
| WO (2) | WO2006074249A1 (https=) |
| ZA (2) | ZA200704487B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8198247B2 (en) | 2004-12-21 | 2012-06-12 | Telik, Inc. | Process for and intermediates in the preparation of canfosfamide and its salts |
| BRPI0606520A2 (pt) * | 2005-01-06 | 2009-06-30 | Telik Inc | tripeptìdeo e tetrapeptìdeo tioéteres |
| US20070154963A1 (en) * | 2005-12-30 | 2007-07-05 | Danying Cai | Method to determine whether a compound is a cellular GSTpi inhibitor |
| US20090221703A1 (en) | 2006-07-09 | 2009-09-03 | Chongxi Yu | High penetration composition and uses thereof |
| US20090238763A1 (en) | 2006-07-09 | 2009-09-24 | Chongxi Yu | High penetration compositions and uses thereof |
| WO2008056207A1 (en) * | 2006-11-08 | 2008-05-15 | Chongxi Yu | Transdermal delivery systems of peptides and related compounds |
| AU2016213759B2 (en) * | 2006-11-08 | 2018-03-29 | Chongxi Yu | Transdermal delivery systems of peptides and related compounds |
| WO2008149181A1 (en) | 2007-06-04 | 2008-12-11 | Techfields Inc | Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses |
| WO2010065936A1 (en) | 2008-12-04 | 2010-06-10 | Chongxi Yu | High penetration compositions and their applications |
| DE102008060888A1 (de) | 2008-12-09 | 2010-06-10 | Evonik Stockhausen Gmbh | Verfahren zur Herstellung von Acrolein umfassend die Aufarbeitung einer Rohglycerin-Phase |
| EP2427475B1 (en) | 2009-05-08 | 2020-11-04 | Techfields Biochem Co., Ltd. | High penetration prodrug compositions of peptides and peptide-related compounds |
| CA2797458A1 (en) * | 2010-06-07 | 2011-12-15 | Telik, Inc. | Tablet formulation of ezatiostat |
| JP2013528214A (ja) | 2010-06-07 | 2013-07-08 | テリック，インコーポレイテッド | 結晶性エザチオスタット塩酸塩非溶媒和物ｄ型の調製 |
| US20130035389A1 (en) * | 2011-08-05 | 2013-02-07 | Telik, Inc. | Methods for treating myelodysplastic syndrome with ezatiostat |
| JP5970439B2 (ja) * | 2013-09-20 | 2016-08-17 | チョンシー ユー | ペプチド及び関連化合物の経皮送達システム |
| CN106146616A (zh) * | 2015-04-03 | 2016-11-23 | 浙江海正药业股份有限公司 | 环肽类化合物及其制备和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5599903A (en) | 1992-04-03 | 1997-02-04 | Terrapin Technologies, Inc. | Glutathione analogs and paralog panels comprising glutathione mimics |
| US5556942A (en) | 1991-04-29 | 1996-09-17 | Terrapin Technologies, Inc. | Glutathione S-transferase-activated compounds |
| US5786336A (en) * | 1991-04-29 | 1998-07-28 | Terrapin Technologies, Inc. | Target-selective protocols based on mimics |
| US5955432A (en) | 1992-04-03 | 1999-09-21 | Terrapin Technologies, Inc. | Metabolic effects of certain glutathione analogs |
| US5767086A (en) | 1992-04-03 | 1998-06-16 | Terrapin Technologies, Inc. | Bone marrow stimulation by certain glutathione analogs |
| CA2105492C (en) * | 1993-09-03 | 2000-02-01 | Lawrence M. Kauvar | Glutathione analogs and paralog panels comprising glutathione mimics |
| US5908919A (en) * | 1993-10-01 | 1999-06-01 | Terrapin Technologies | Urethane mediated, GST specific molecular release systems |
| JPH11507056A (ja) * | 1995-06-07 | 1999-06-22 | テラピン テクノロジーズ、インク． | グルタチオンアナログの代謝的効果 |
| AU4124697A (en) * | 1996-09-02 | 1998-03-26 | Manchester Metropolitan University, The | S-blocked glutathiones |
| TW576838B (en) * | 1998-04-16 | 2004-02-21 | Teijin Ltd | Glutathione derivatives and application form thereof |
| ATE286741T1 (de) | 1999-01-27 | 2005-01-15 | Telik Inc | Glutathioneanaloge enthaltende therapeutische zusammensetzungen |
| US7029695B2 (en) | 2001-07-10 | 2006-04-18 | Telik, Inc. | Therapeutic compositions containing glutathione analogs |
| TWI323662B (en) * | 2002-11-15 | 2010-04-21 | Telik Inc | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
| BRPI0606520A2 (pt) * | 2005-01-06 | 2009-06-30 | Telik Inc | tripeptìdeo e tetrapeptìdeo tioéteres |
-
2006
- 2006-01-04 BR BRPI0606520-1A patent/BRPI0606520A2/pt not_active IP Right Cessation
- 2006-01-04 AT AT06717426T patent/ATE410520T1/de active
- 2006-01-04 HR HR20090128T patent/HRP20090128T3/xx unknown
- 2006-01-04 CN CN2006800014949A patent/CN101090977B/zh not_active Expired - Fee Related
- 2006-01-04 PL PL06717426T patent/PL1833978T3/pl unknown
- 2006-01-04 MX MX2007008255A patent/MX2007008255A/es active IP Right Grant
- 2006-01-04 DE DE602006003064T patent/DE602006003064D1/de not_active Expired - Lifetime
- 2006-01-04 TW TW095100278A patent/TWI317739B/zh not_active IP Right Cessation
- 2006-01-04 DK DK06717426T patent/DK1833978T3/da active
- 2006-01-04 WO PCT/US2006/000219 patent/WO2006074249A1/en not_active Ceased
- 2006-01-04 SI SI200630153T patent/SI1833978T1/sl unknown
- 2006-01-04 JP JP2007550441A patent/JP4903716B2/ja not_active Expired - Fee Related
- 2006-01-04 NZ NZ555362A patent/NZ555362A/en not_active IP Right Cessation
- 2006-01-04 KR KR1020077018022A patent/KR101244609B1/ko not_active Expired - Fee Related
- 2006-01-04 TW TW095100277A patent/TWI317738B/zh not_active IP Right Cessation
- 2006-01-04 US US11/325,846 patent/US7129215B2/en not_active Expired - Fee Related
- 2006-01-04 AU AU2006204022A patent/AU2006204022B2/en not_active Ceased
- 2006-01-04 EP EP06717426A patent/EP1833978B1/en not_active Expired - Lifetime
- 2006-01-04 PT PT06717426T patent/PT1833978E/pt unknown
- 2006-01-04 ES ES06717426T patent/ES2314890T3/es not_active Expired - Lifetime
- 2006-01-04 EA EA200701398A patent/EA200701398A1/ru unknown
- 2006-01-04 CA CA2587284A patent/CA2587284C/en not_active Expired - Fee Related
- 2006-01-05 BR BRPI0606396-9A patent/BRPI0606396A2/pt not_active IP Right Cessation
- 2006-01-05 DK DK06717699T patent/DK1833842T3/da active
- 2006-01-05 NZ NZ555361A patent/NZ555361A/en not_active IP Right Cessation
- 2006-01-05 US US11/326,975 patent/US7192918B2/en not_active Expired - Fee Related
- 2006-01-05 EA EA200701399A patent/EA200701399A1/ru unknown
- 2006-01-05 PT PT06717699T patent/PT1833842E/pt unknown
- 2006-01-05 AU AU2006203901A patent/AU2006203901B2/en not_active Ceased
- 2006-01-05 HR HR20090134T patent/HRP20090134T3/xx unknown
- 2006-01-05 KR KR1020077012531A patent/KR20070091611A/ko not_active Ceased
- 2006-01-05 ES ES06717699T patent/ES2314891T3/es not_active Expired - Lifetime
- 2006-01-05 WO PCT/US2006/000532 patent/WO2006074409A1/en not_active Ceased
- 2006-01-05 JP JP2007550515A patent/JP4903717B2/ja not_active Expired - Fee Related
- 2006-01-05 DE DE602006003063T patent/DE602006003063D1/de not_active Expired - Lifetime
- 2006-01-05 CN CNA2006800013664A patent/CN101080418A/zh active Pending
- 2006-01-05 SI SI200630154T patent/SI1833842T1/sl unknown
- 2006-01-05 PL PL06717699T patent/PL1833842T3/pl unknown
- 2006-01-05 AT AT06717699T patent/ATE410440T1/de active
- 2006-01-05 CA CA2587310A patent/CA2587310C/en not_active Expired - Fee Related
- 2006-01-05 EP EP06717699A patent/EP1833842B1/en not_active Expired - Lifetime
- 2006-01-05 AR ARP060100041A patent/AR051889A1/es not_active Application Discontinuation
- 2006-01-05 MX MX2007008254A patent/MX2007008254A/es active IP Right Grant
- 2006-01-05 AR ARP060100042A patent/AR051890A1/es not_active Application Discontinuation
-
2007
- 2007-04-26 IL IL182836A patent/IL182836A/en not_active IP Right Cessation
- 2007-05-10 IL IL183107A patent/IL183107A/en not_active IP Right Cessation
- 2007-05-20 ZA ZA200704487A patent/ZA200704487B/xx unknown
- 2007-05-30 ZA ZA200704488A patent/ZA200704488B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR051889A1 (es) | Sulfonas de tripeptido y tetrapeptido | |
| CY1112084T1 (el) | Παραγωγα 5-φαινυλθειαζολης και χρηση ως αναστολεις της κινασης ρi3 | |
| AR076778A1 (es) | Composiciones orales que contienen compuestos de poliguanidinio y metodos de preparacion y uso de las mismas | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| AR029210A1 (es) | DERIVADOS DE N-(5-SULFAMOIL-1,3-TIAZOL-2-IL) ACETAMIDA, PROCEDIMIENTO PARA SU PREPARACIoN, COMPUESTOS INTERMEDIARIOS, COMPOSICIoN FARMACÉUTICA, Y EL USO DE DICHOS DERIVADOS PARA LA PRODUCCIoN DE MEDICAMENTOS | |
| ATE448199T1 (de) | Verbindungen mit taxol-verstärkender wirkung | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| ECSP066314A (es) | Derivados piridilo y su uso como agentes terapéuticos | |
| AR033499A1 (es) | Derivado de quinazolina, proceso para su preparacion, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para usar en la produccion de un efecto antiangeogenico y/o reductor de la permeabilidad vascular en un animal de sangre caliente | |
| ATE532790T1 (de) | Einschlussverbindung mit cucurbiturilderivaten als wirtsmolekül, und diese enthaltende pharmazeutische zusammensetzung | |
| EA200100983A1 (ru) | Производные 13-метилэритромицина | |
| UY31334A1 (es) | 3a,4,5,6,7,7a-hexahidro-3h-benzoimidazol y derivaods de 3a, 4,5,6,,7,7a-hexahidro-3-indol, enantiómeros, diastereoisómeros, sales farmacéuticamente aceptadas, mezclas, composiciones, preparaciones y aplicaciones de las mismas | |
| NO20070837L (no) | Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer. | |
| CY1109366T1 (el) | Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης | |
| SE0402925D0 (sv) | Novel Compounds | |
| EA200700901A1 (ru) | Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии | |
| PT992509E (pt) | Novos derivados macrolidos | |
| BR0314352A (pt) | Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6 | |
| GEP20074058B (en) | 4-(7-halo-2-quino(xa) linyloxy-phenoxy-propionic acid derivatives as antineoplastic agents | |
| AR035524A1 (es) | Sulfamidotienopirimidinas, un procedimiento para su preparacion, el uso de las mismas para la preparacion de un medicamento, los medicamentos que las comprenden, un conjunto (kit) que las incluye, las preparaciones farmaceuticas que las contienen, y un procedimiento para preparar estas preparaciones | |
| BR0113987A (pt) | Composto heteromático bicìclico, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de derivados heteroaromáticos bicìclicos ou de um sal ou solvato farmaceuticamente aceitável dos mesmos | |
| ES2170758T3 (es) | Antibioticos novedosos de cefalosporina y procedimientos para la preparacion de los mismos. | |
| AR046212A1 (es) | Derivados de 2-fenilbenzofurano, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| ATE307131T1 (de) | Phenanthrolin-7-onderivate und ihre therapeutische verwendung | |
| AR042617A1 (es) | Disorazoles y sus derivados, utiles para el tratamiento de enfermedades tumorales benignas y malignas, y el uso de dichos compuestos para la preparacion de medicamentos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |